secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-07-01T20:11:51+00:00
Accession:  0001034842-26-000045
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Pharmaceuticals appoints Alison Hannah as EVP, CMO; Lisa Rojkjaer departs
-------------------------------------------------------------------------------

- Alison L. Hannah, M.D. appointed Executive Vice President and Chief Medical Officer effective July 1, 2026.
- Dr. Hannah resigned from the Board of Directors effective July 1, 2026; she had served as a board member since May 2021.
- Lisa Rojkjaer, M.D. ceased as EVP and CMO and separated from the company effective June 25, 2026.
- Dr. Hannah previously served as CMO of CytomX Therapeutics and as a consultant to the pharmaceutical and biotechnology industry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/rigl-20260625.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer